Nitrocatechol Derivatives for COMT Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current COMT inhibitors for Parkinson's disease, such as tolcapone, face challenges with liver toxicity and short duration of action, leading to inadequate bioavailability and efficacy, while safer alternatives like entacapone have limited potency and require high doses.
Innovation Solution
Development of novel substituted nitrocatechol derivatives with a specific chemical formula that inhibit catechol-O-methyltransferase (COMT), enhancing L-DOPA bioavailability and brain delivery with a prolonged duration of action, avoiding liver toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tolcapone is used as a COMT inhibitor, then COMT inhibition potency is improved, but liver toxicity increases
Solution Approach 1:
The patent modifies the chemical structure of tolcapone by replacing the phenyl ring with various heteroaryl groups (pyridine, pyrimidine, triazole, oxadiazole, thiadiazole), which changes the pharmacological properties to reduce liver toxicity while maintaining COMT inhibition potency. These structural parameter changes allow the compound to retain enzyme binding affinity while avoiding toxic metabolic pathways.
Solution Approach 2:
The patent creates composite molecular structures combining the nitrocatechol pharmacophore with diverse heteroaryl moieties linked through various connectors. This composite approach allows optimization of both potency and safety profiles by integrating functional elements that contribute to enzyme inhibition while reducing adverse effects.
2Object-affected harmful factors
If entacapone is used as a COMT inhibitor, then liver toxicity is reduced, but COMT inhibition potency decreases
Solution Approach 1:
The patent enhances the potency of entacapone-like structures by introducing electron-withdrawing heteroaryl groups and optimizing the connector between the nitrocatechol and heteroaryl moieties. These parameter changes increase the affinity for COMT enzyme while maintaining the safety profile of not penetrating the blood-brain barrier.
Solution Approach 2:
The patent creates derivative compounds that copy the successful safety profile of entacapone (peripheral selectivity, low brain penetration) while incorporating structural modifications to enhance potency through improved enzyme binding interactions.
3Duration of action of moving object
If L-DOPA dosage is increased to extend duration of action, then duration of action is improved, but bioavailability decreases due to competition at BBB transport
Solution Approach 1:
The patent uses COMT inhibition as an intermediary mechanism to protect L-DOPA from peripheral metabolism. By blocking COMT, more L-DOPA remains available for transport across the blood-brain barrier, effectively increasing brain delivery without increasing the L-DOPA dose and avoiding saturation of transport systems.
Solution Approach 2:
The patent achieves continuous protection of L-DOPA throughout the dosing interval through sustained COMT inhibition. This continuous mechanism ensures steady levels of L-DOPA available for brain transport, eliminating the wearing-off effect and maintaining therapeutic action throughout the extended dosing interval.
4Adaptability or versatility
If COMT inhibitors penetrate into the brain, then central COMT inhibition is achieved, but CNS side effects increase
Solution Approach 1:
The patent achieves local quality by designing compounds with selective distribution: the nitrocatechol-heteroaryl structures are potent enough to inhibit peripheral COMT effectively but are engineered to have low affinity for CNS transport systems. This creates a therapeutic window where peripheral action is maximized while central side effects are minimized.
Solution Approach 2:
The patent employs compounds that act as disposable peripheral inhibitors—these molecules are eliminated from the body before they can accumulate to levels that would cause CNS toxicity, allowing repeated dosing without progressive central side effects.
Data Source
AI summary
This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.